Stockscreener 앱 받기
0.78
3.68%
-0.0298
전일 마감가:
$0.8098
열려 있는:
$0.8002
하루 거래량:
128.85K
Relative Volume:
0.07
시가총액:
$4.57M
수익:
$4.70M
순이익/손실:
$-4.99M
주가수익비율:
-0.1215
EPS:
-6.42
순현금흐름:
$-5.29M
1주 성능:
-5.45%
1개월 성능:
-32.17%
6개월 성능:
-92.64%
1년 성능:
-96.39%
1일 변동 폭
$0.78
$0.81
1주일 범위
$0.78
$0.89
52주 변동 폭
$0.7106
$108.00
Salarius Pharmaceuticals Inc Stock (SLRX) Company Profile
명칭
Salarius Pharmaceuticals Inc
전화
346-772-0346
주소
2450 HOLCOMBE BLVD, HOUSTON
SLRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SLRX
Salarius Pharmaceuticals Inc
|
0.78 | 4.75M | 4.70M | -4.99M | -5.29M | -6.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Salarius Pharmaceuticals Inc Stock (SLRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-04-27 | 개시 | Ladenburg Thalmann | Buy |
Salarius Pharmaceuticals Inc 주식(SLRX)의 최신 뉴스
Salarius Pharmaceuticals Inc. (SLRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Taking the lead: Salarius Pharmaceuticals Inc (SLRX) - setenews.com
Salarius Pharmaceuticals (NASDAQ:SLRX) Upgraded at Wall Street Zen - Defense World
Why Salarius Pharmaceuticals Inc. stock is a must watch in 20252025 Trade Ideas & Real-Time Chart Breakout Alerts - Newser
Can Salarius Pharmaceuticals Inc. (FP10) stock resist broad market declinesTrend Reversal & Accurate Entry/Exit Alerts - Newser
Is Salarius Pharmaceuticals Inc. stock attractive for income investorsProduct Launch & Daily Entry Point Alerts - Newser
Can Salarius Pharmaceuticals Inc. (FP10) stock sustain breakout momentumJuly 2025 Reactions & AI Powered Market Entry Ideas - Newser
Salarius Pharmaceuticals (SLRX) Stock Analysis Report | Financials & Insights - Benzinga
How Salarius Pharmaceuticals Inc. (FP10) stock responds to job market shiftsWeekly Volume Report & Smart Money Movement Alerts - Newser
Salarius Pharmaceuticals, Inc. (SLRX) 7.9% in After-hours: Collaboration with Texas Biomedical Research Institute Sparks Interest - Stocks Telegraph
Salarius Pharmaceuticals' Decoy Unit Partners With Texas Biomed on Flu Inhibitor Testing - marketscreener.com
Salarius Pharmaceuticals to collaborate with Texas Biomedical Research Institute on avian flu study - marketscreener.com
SLRX Collaborates with Texas Research Institute for Influenza Te - GuruFocus
Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study - GlobeNewswire
Salarius (Nasdaq: SLRX) teams with Texas Biomed on H5N1 avian flu inhibitor testing - Stock Titan
Will Salarius Pharmaceuticals Inc. stock benefit from infrastructure spending2025 Trade Ideas & AI Forecasted Entry and Exit Points - moha.gov.vn
Is Salarius Pharmaceuticals Inc. stock affected by interest rate hikes2025 Price Action Summary & Consistent Profit Trading Strategies - moha.gov.vn
Hanish of Salarius Pharma buys $3740 in shares - Investing.com India
Hanish of Salarius Pharma buys $3740 in shares By Investing.com - Investing.com South Africa
[Form 4] Salarius Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
What analysts say about Salarius Pharmaceuticals Inc stockDividend Yield Trends & Technical + Fundamental = Smarter Investing - earlytimes.in
Salarius Pharmaceuticals Inc (SLRX) can make a big difference with a little luck - Setenews
[Form 3] Salarius Pharmaceuticals, Inc. Initial Statement of Beneficial Ownership - Stock Titan
SLRX Stock Institutional Owners - Quiver Quantitative
How Salarius Pharmaceuticals Inc. stock reacts to inflationary pressuresJuly 2025 PostEarnings & Free AI Powered Buy and Sell Recommendations - newser.com
Salarius Pharmaceuticals Exec VP Finance, CFO Mark J Rosenblum Acquires 20,000 Shares - TradingView
Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol SLRX - MarketScreener
Why Salarius Pharmaceuticals Inc. (FP10) stock stays resilientJuly 2025 Intraday Action & AI Enhanced Market Trend Forecasts - newser.com
Salarius Pharmaceuticals (NASDAQ:SLRX) Stock Price Down 8.3% – Here’s Why - Defense World
Will Salarius Pharmaceuticals Inc. (FP10) stock benefit from infrastructure bill - newser.com
Ranking Salarius Pharmaceuticals Inc. among high performing stocks via toolsProduct Launch & Stepwise Entry/Exit Trade Alerts - newser.com
When is the best time to exit Salarius Pharmaceuticals Inc.Market Trend Summary & Free Weekly Watchlist of Top Performers - newser.com
What catalysts could drive Salarius Pharmaceuticals Inc. stock higher - newser.com
Applying Elliott Wave Theory to Salarius Pharmaceuticals Inc.Portfolio Profit Report & Low Risk Profit Maximizing Plans - newser.com
Salarius clarifies Nasdaq listing status, refutes S&P CapIQ error By Investing.com - Investing.com Australia
Salarius Pharmaceuticals Inc (SLRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.08%
0.91%
자본화:
|
볼륨(24시간):